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Objective
To improve on the existing risk-stratification systems for
prostate cancer.
Patients and Methods
This was a retrospective investigation including 2 248 patients
undergoing dose-escalated external beam radiotherapy
(EBRT) at a single institution. We separated National
Comprehensive Cancer Network (NCCN) intermediate-risk
prostate cancer into ‘favourable’ and ‘unfavourable’ groups
based on primary Gleason pattern, percentage of positive
biopsy cores (PPBC), and number of NCCN intermediate-risk
factors. Similarly, NCCN high-risk prostate cancer was
stratified into ‘standard’ and ‘very high-risk’ groups based on
primary Gleason pattern, PPBC, number of NCCN high-risk
factors, and stage T3b–T4 disease. Patients with unfavourable-
intermediate-risk (UIR) prostate cancer had significantly
inferior prostate-specific antigen relapse-free survival
(PSA-RFS, P < 0.001), distant metastasis-free survival (DMFS,
P < 0.001), prostate cancer-specific mortality (PCSM,
P < 0.001), and overall survival (OS, P < 0.001) compared
with patients with favourable-intermediate-risk (FIR) prostate
cancer. Similarly, patients with very high-risk (VHR) prostate
cancer had significantly worse PSA-RFS (P < 0.001), DMFS
(P < 0.001), and PCSM (P = 0.001) compared with patients
with standard high-risk (SHR) prostate cancer. Moreover,
patients with FIR and low-risk prostate cancer had similar
outcomes, as did patients with UIR and SHR prostate cancer.
Results
Consequently, we propose the following risk-stratification
system: Group 1, low risk and FIR; Group 2, UIR and SHR;
and Group 3, VHR. These groups have markedly different
outcomes, with 8-year distant metastasis rates of 3%, 9%, and
29% (P < 0.001) for Groups 1, 2, and 3, respectively, and 8-
year PCSM of 1%, 4%, and 13% (P < 0.001) after EBRT. This
modified stratification system was significantly more accurate
than the three-tiered NCCN system currently in clinical use
for all outcomes.
Conclusion
Modifying the NCCN risk-stratification system to group FIR
with low-risk patients and UIR with SHR patients, results in
modestly improved prediction of outcomes, potentially
allowing better personalisation of therapeutic
recommendations.
Keywords
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Introduction
Prostate cancer represents one of the most heterogeneous
diseases in oncology, exhibiting a wide diversity in clinical
behaviour. Many prostate cancers have essentially no
metastatic potential and are unlikely to impact overall
mortality even if untreated [1,2], whereas others are highly
lethal and eventually become refractory to all known
therapies [3,4]. To cope with this heterogeneity, risk-
stratification systems aid in distinguishing indolent from
aggressive tumours. These systems play critical roles in both
prognostication and therapeutic recommendations.
The National Comprehensive Cancer Network (NCCN)
risk-stratification system has been widely utilised for many
years [5]. Although its prognostic accuracy has been
reproducibly validated in numerous settings, clinical
heterogeneity, particularly within the intermediate-risk (IR)
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and high-risk (HR) groups, is well established [4,6–8]. This
is partly because the traditional NCCN system does not
incorporate primary Gleason pattern or percentage of
positive biopsy cores (PPBC), which have been repeatedly
validated as critical prognostic factors in independent
datasets [7,9–11].
Therefore, several modifications of the NCCN system have
recently been proposed. For example, Zumsteg and Zelefsky
[7,8,12] have proposed stratifying NCCN IR disease into
‘favourable’ and ‘unfavourable’ subgroups based on primary
Gleason pattern, PPBC, and number of NCCN IR factors. In
addition, the NCCN has recently recognised a ‘very-high-risk’
(VHR) group [4,5]. Although the proposed dichotomisation
of the IR group has been validated in several independent
datasets [13,14], the validity of the NCCN VHR definition
has been less rigorously examined, especially in patients
undergoing radiotherapy.
These refinements have the potential to improve
personalisation of therapeutic recommendations by more
accurately determining the inherent aggressiveness of a
patient’s prostate cancer. However, there is also increased
complexity, and the implications of these new divisions
within risk groups for therapeutic recommendations are
unclear. Further, given that different institutions have
proposed disparate modifications, it is unclear how these
proposed modifications relate to one another or to the
original NCCN risk groups. To overcome these challenges, we
sought to simplify updated risk-stratification modifications to
the dichotomised IR and HR groups, and create a single
unified risk-stratification system.
Patients and Methods
Patient Selection
The study cohort included 2 248 patients with localised
prostate cancer and complete biopsy core information
undergoing external beam radiotherapy (EBRT) with doses of
≥75.6 Gy at Memorial Sloan Kettering Cancer Center
(MSKCC) from 1991 to 2010. Institutional Review Board
approval was obtained before initiation of the project.
Risk Stratification
Low-risk (LR), IR, and HR groups were defined as per the
NCCN system [5]. Unfavourable-IR (UIR) disease was
defined as NCCN IR disease and any of the following
unfavourable risk factors: primary Gleason pattern of 4, ≥50%
PPBC, or ≥2 NCCN IR factors (clinical stage T2b or T2c,
total Gleason score = 7 or PSA level = 10–20 ng/mL) [7,8].
All other IR patients were defined as having favourable-IR
(FIR) disease. VHR prostate cancer was defined as a patient
with NCCN HR disease and any of the following: clinical
stage T3b–T4, primary Gleason pattern of 5, ≥50% PPBC, or
≥2 NCCN HR factors (clinical stage T3–T4, total Gleason
score ≥8 or a PSA level >20 ng/mL). HR patients not meeting
VHR criteria were considered to have standard-HR (SHR)
disease.
Staging and Treatment
At our institution, the departmental policy during the
period of this study was that all patients receive imaging of
the pelvis with MRI or CT before consultation. The
radiation techniques used at our institution have been
described in detail previously [7,11]. In brief, patients were
immobilised in the supine position using an Aquaplast
mould and underwent CT-based treatment planning.
Treatment was delivered with intensity modulation,
typically using 15 MV photons, to the prostate and seminal
vesicles and in general the pelvic lymph nodes were not
electively treated in this patient cohort. Patients with node-
positive disease based on pretreatment studies including CT
or pelvic MRI were excluded from this study. Androgen-
deprivation therapy (ADT) was administered at the
discretion of the treating physician. When used, ADT
generally was administered both neoadjuvantly and
concurrently, with a median duration of 6 months.
Endpoints
The Phoenix definition of PSA recurrence was used for this
study [15]. Distant metastasis (DM) was defined as any
clinically detectable site of prostate cancer occurring outside
of the prostate, seminal vesicles, or pelvic lymph nodes.
Confirmation of DM required biopsy of at least one site,
response to ADT initiation, or clinical plus rising PSA in
castration-resistant disease. Prostate cancer-specific mortality
(PCSM) was defined as death either from causes directly
related to prostate cancer progression or from unknown
causes in castration-resistant disease. Time to all events was
measured from the end of EBRT.
Statistical Methods
The primary purpose of this study was to define risk
groups that more accurately predict DM and PCSM after
EBRT than the current NCCN system. Kaplan–Meier
analysis was used to estimate PSA relapse-free survival
(PSA-RFS), DM-free survival (DMFS), and overall survival
(OS), and a Cox proportional hazards model was used for
univariate and multivariate analyses. The log-rank test was
used to compare risk subgroups. PCSM was evaluated using
competing-risks analyses. The risk of PCSM was estimated
using a cumulative-incidence function that accounted for
death due to other causes and compared using Gray’s test.
The Fine and Gray method was used for univariate and
multivariate analyses. The discriminatory abilities of the
NCCN risk group and the proposed MSKCC risk group for
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PSA-RFS, DMFS, and OS were evaluated using G€onen and
Heller’s [16] concordance probability estimate (CPE) and
compared using bootstrap methods. The discriminatory
abilities of the two risk-group systems for PCSM were
evaluated using the Wolbers et al. [17] c-index for
regression in the presence of competing risks and compared
using bootstrap methods. Separate multivariate models were
built using the patient factors of interest or risk group plus
treatment variables. Statistical analyses were performed using
R (version 3.2.0; R Foundation for Statistical Computing,
Vienna, Austria).
Results
The baseline characteristics are summarised in Table 1. The
median follow-up for survivors from the end of EBRT was
7.4 years. In all, 480 patients were LR, 1 166 IR, and 602 HR
per the NCCN criteria. Of those with IR disease, 481 and 685
were classified as FIR and UIR, respectively. In all, 436
patients with HR prostate cancer were classified as VHR.
Given that our proposed stratification for both IR and HR
prostate cancer uses primary Gleason pattern and PPBC, two
variables not included in the NCCN system, we sought to
study the importance of these variables amongst other
standard prognostic variables. In multivariate analysis, only
clinical stage T3b–T4, primary Gleason pattern, and PPBC of
≥50% predicted for both DMFS and PCSM (Table 2),
validating these variables as excellent candidates for risk-
stratification determinates.
We next analysed outcomes for patients stratified by LR, FIR,
UIR, SHR, and VHR disease (Fig. 1, Table 3). We found that
VHR patients had significantly worse PSA-RFS (P < 0.001),
DMFS (P < 0.001), and PCSM (P = 0.001) than SHR
patients, validating these groups as distinct in terms of
prostate cancer prognosis after EBRT. Similarly, patients with
UIR had significantly worse PSA-RFS (P < 0.001), DMFS
(P < 0.001), and PCSM (P < 0.001) than those with FIR.
Although there was no difference in OS when comparing
SHR and VHR patients (P = 0.29), UIR patients had
significantly worse OS than FIR patients (P < 0.001). These
results were similar when adjusting for differences in ADT
use between these subgroups. In contrast, in our cohort we
found no difference in outcome when comparing the LR and
FIR groups for PSA-RFS (89.1% vs 88.3% at 8 years,
P = 0.84), DMFS (2.3% vs 2.8%, P = 0.46), PCSM (0.8% vs
1.5%, P = 0.80), or OS (89.6% vs 88.2%, P = 0.91). Similarly,
we found no significant difference when comparing the UIR
and SHR groups for PSA-RFS (74.2% vs 80.3% at 8 years,
P = 0.16), DMFS (7.8% vs 12.0%, P = 0.44), PCSM (4.0% vs
3.0%, P = 0.54), or OS (79.6% vs 76.6%, P = 0.87). These
results persisted even after correcting for ADT use amongst
the cohorts.
Given these results, we defined a risk-stratification system
that groups LR patients with FIR patients (Group 1) and UIR
patients with SHR patients (Group 2), and separating VHR
patients into their own group (Group 3). These groups had
highly statistically significant differences (P < 0.001) in all
pairwise comparisons for PSA-RFS, DMFS, PCSM, and OS
(Table 4, Fig. 2), except when comparing OS for Group 2
and Group 3 (P = 0.091).
For all endpoints, our modified system was significantly, but
modestly, more accurate in predicting PSA-RFS (CPE = 0.651
vs 0.623, bootstrap P < 0.001), DMFS (CPE = 0.693 vs 0.662,
bootstrap P = 0.005), PCSM (CPE = 0.736 vs 0.701, bootstrap
P = 0.002), and OS (CPE 0.587 vs 0.566, bootstrap P = 0.003)
than the classic NCCN system (Table S1).
Discussion
In the present study, comprising a large cohort of patients
undergoing dose-escalated EBRT, we validated IR and HR
prostate cancer as heterogeneous groups subclassifiable based
on the primary Gleason pattern, PPBC, number of NCCN
Table 1 Baseline clinical and pathological characteristics.
Variable N (%)
Total patients 2 248
Age, years
<60 235 (10)
60–70 982 (44)
>70 1 031 (46)
NCCN risk group
Low 480 (21)
Intermediate 1 166 (52)
Favourable 481 (21)
Unfavourable 685 (30)
High 602 (27)
Standard 166 (7)
Very high 436 (19)
Tumour stage
≤T2a 1 662 (74)
T2b–T3a 466 (21)
T3b–T4 120 (5)
Total Gleason score
≤6 795 (35)
7 1 088 (48)
8 220 (10)
9–10 145 (6)
Primary Gleason pattern
≤3 1 506 (67)
4 693 (31)
5 49 (2)
PSA level, ng/mL
<10 1 450 (65)
10–20 531 (24)
≥20 267 (12)
Radiation dose, Gy
<81 196 (9)
81–86 2 052 (91)
ADT
No 1 008 (45)
Yes 1 240 (55)
PPBC
<50 1 452 (65)
≥50 796 (35)
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risk factors, and presence of gross invasion into adjacent
structures, such as seminal vesicles, bladder, or rectum. These
substratification groups identify patients within the IR and
HR groups that have markedly different rates of PSA-RFS,
DMFS, and PCSM. Additionally, we found that patients with
FIR disease had identical prognoses to those with LR disease,
and UIR patients have outcomes similar to SHR patients after
EBRT. Thus, we propose a modified risk-stratification system
that integrates NCCN LR and FIR patients (Group 1) and
UIR and SHR patients (Group 2), and separates VHR
patients into a distinct group (Group 3). These groups stratify
patients into categorisations with markedly different
prognoses. For example, about 3%, 9%, and 29% of patients
in Groups 1, 2, and 3, respectively, will experience DM and
1%, 4%, and 13% will experience PCSM within 8 years of
EBRT. For all outcomes, this modified risk-stratification
system had better predictive capability than the standard
three-tiered NCCN system.
Our present modified risk-stratification system has
important practical implications for therapeutic
recommendations. First, we think that the notion that all
NCCN IR prostate cancer represents clinically significant
disease requiring aggressive local treatment may warrant
reconsideration. In our present cohort, patients with FIR
prostate cancer had identical outcomes to those with LR
disease, with an 8-year risk of DM and PCSM of 2.8% and
1.5%, respectively, after EBRT. Similarly, another recent
study reported that patients with FIR disease undergoing
brachytherapy had outcomes identical to LR patients, with
PCSM occurring in 0.5% of FIR at 8 years. This suggests
that single-modality therapy EBRT is sufficient to eradicate
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Fig. 1 LR, FIR, UIR, SHR, and VHR patient outcomes after definitive dose-escalated EBRT. (A) PSA-RFS. (B) DM. (C) PCSM. (D) OS.
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FIR disease in the vast majority of patients. Moreover,
although equivalent outcomes after definitive radiation for
LR and FIR prostate cancer do not necessarily mean that
they will have equivalent outcomes without up-front
treatment, we think active surveillance for FIR warrants
further investigation. In fact, several prospective studies of
active surveillance have included selected patients with IR
disease, and low rates of disease-specific mortality have been
reported [1,18–20]. In addition, the Prostate Testing for
Cancer and Treatment (ProtecT) study, which enrolled a
substantial number of IR patients, showed similar PCSM
rates of ~1% of patients at 10 years with either active
surveillance or definitive treatment [21]. Given that FIR
patients have an extremely low incidence of DM and PCSM
after treatment, combined with the lack of benefit reported
from the addition of ADT in this population [7,12,14], we
think single-modality therapy with EBRT, brachytherapy, or
surgery is appropriate for FIR patients who choose to
undergo definitive treatment.
By contrast, Group 3 patients with VHR prostate cancer,
representing nearly 20% of the patients treated at our
institution with EBRT over the past two decades, have poor
outcomes even with dose-escalated EBRT and ADT. At
8 years after EBRT, about half of these patients had PSA
relapse, nearly one in three had DM, and one in eight had
PCSM. Clearly, novel therapeutic paradigms are needed.
Given their high risk of DM, the VHR population represents
an ideal cohort to study second-generation anti-androgens,
chemotherapy, and other novel systemic therapies in the
definitive setting. However, another possible, and
complementary approach, would be to further escalate local
therapy to maximise eradication of the primary tumour.
Despite the conventional notion that local control is less
important in patients with a high risk of subclinical
micrometastases at presentation, the most common initial
recurrence site for patients with NCCN HR disease is the
prostate itself [22]. Multiple randomised Phase III clinical
trials have shown that adding radiotherapy to ADT
significantly improves survival in patients with HR prostate
cancer compared with ADT alone [23,24]. Therefore, we
think that trimodality approaches, such as combined EBRT,
brachytherapy, and ADT, or prostatectomy followed by
adjuvant EBRT and ADT, could improve clinical outcomes in
VHR patients.
Table 3 Survival outcomes according to risk group.
8-year
estimate, %
HR 95% CI P
PSA-RFS
LR 89.1 1.00 Reference –
FIR 88.3 0.92 0.63, 1.35 0.67
UIR 74.2 2.26 1.67, 3.06 <0.001
SHR 80.3 1.70 1.09, 2.66 0.019
VHR 49.4 5.36 4.39, 7.05 <0.001
DM
LR 2.3 1.00 Reference –
FIR 2.8 0.74 0.35, 1.59 0.44
UIR 7.8 2.70 1.56, 4.64 <0.001
SHR 12.0 3.38 1.73, 6.63 <0.001
VHR 29.2 9.31 5.61, 15.47 <0.001
PCSM
LR 0.8 1.00 Reference –
FIR 1.5 1.18 0.34, 4.07 0.79
UIR 4.0 5.67 2.23, 14.41 <0.001
SHR 3.0 4.36 1.38, 13.74 0.012
VHR 12.5 14.38 5.80, 35.66 <0.001
OS
LR 89.6 1.00 Reference –
FIR 88.2 0.95 0.70, 1.31 0.77
UIR 79.6 1.83 1.42, 2.36 <0.001
SHR 76.6 1.87 1.31, 2.66 <0.001
VHR 70.3 2.18 1.68, 2.82 <0.001
PCSM was analysed using a competing-risks methodology. HR, hazard ratio.
Table 4 Survival outcomes according to the proposed modified risk groupings.
8-year
estimate, %
Unadjusted Adjusted for ADT, RT dose
HR 95% CI P HR 95% CI P
PSA-RFS
Group 1 (LR + FIR) 88.7 1.00 Reference – 1.00 Reference –
Group 2 (UIR + SHR) 75.5 2.23 1.75, 2.84 <0.001 2.57 2.00, 3.29 <0.001
Group 3 (VHR) 49.4 5.56 4.39, 7.05 <0.001 7.46 5.70, 9.77 <0.001
DM
Group 1 (LR + FIR) 2.5 1.00 Reference – 1.00 Reference –
Group 2 (UIR + SHR) 8.6 3.21 2.08, 4.97 <0.001 3.53 2.26, 5.50 <0.001
Group 3 (VHR) 29.2 10.58 7.01, 15.94 <0.001 12.81 8.14, 20.16 <0.001
PCSM
Group 1 (LR + FIR) 1.1 1.00 Reference – 1.00 Reference –
Group 2 (UIR + SHR) 3.8 4.99 2.51, 9.93 <0.001 5.22 2.63, 10.36 <0.001
Group 3 (VHR) 12.5 13.28 6.83, 25.83 <0.001 14.25 7.21, 28.19 <0.001
OS
Group 1 (LR + FIR) 89.0 1.00 Reference – 1.00 Reference –
Group 2 (UIR + SHR) 79.0 1.88 1.53, 2.30 <0.001 1.86 1.51, 2.29 <0.001
Group 3 (VHR) 70.3 2.22 1.79, 2.76 <0.001 2.19 1.73, 2.79 <0.001
HR, hazard ratio.
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The absolute improvement in prediction using the MSKCC
classification system was relatively modest compared with the
NCCN system. Nevertheless, we think that our proposed
classification has several advantages over the NCCN system
beyond mildly improved concordance indices. First, we think
that the MSKCC system more accurately groups together
patients that would benefit from similar therapies than the
NCCN system. Second, the MSKCC classification system
results in risk-group downstaging for many patients. For
example, in our present dataset, the proportion of patients in
the lowest risk tier, Group 1, was twice as high as the
proportion classified as LR by the NCCN system (42% vs
21%). We hope that this system will allow less-aggressive
therapeutic approaches to be recommended by practitioners
in more patients. Additionally, our present system unifies and
simplifies several proposed modifications to the IR and HR
NCCN groups. Lastly, other classification systems, such as the
Candiolo classifier, have reported higher concordance indices
than ours [25]. However, they tend to be much more
complicated than our present system, potentially overfitting
their proposed models to their own datasets and precluding
simple applicability in the clinic. For example, the Candiolo
classification table has 360 different possible combinations
based on clinicopathological features, each mapped to one of
five risk groups. Thus, although our proposed classification is
an incremental modification of the NCCN system, we feel
that it is useful for guiding clinical recommendations.
Our present study has several limitations. First, this is a
retrospective, single-institution study. Additionally, our new
system was not validated by an independent data set. It will be
particularly important to validate these results in a
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Fig. 2 Outcomes for Group 1 (LR and FIR), Group 2 (UIR and SHR), and Group 3 (VHR) after definitive dose-escalated EBRT. (A) PSA-RFS. (B) DM. (C)
PCSM. (D) OS.
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prostatectomy cohort, given that a risk-classification system
should be applicable all men with localised prostate cancer.
However, we note that many of our present findings have been
separately validated in part by outside groups using
independent patients cohorts, including the divergent
prognoses of FIR and UIR prostate cancer [13,14], and the
similar outcomes of LR and FIR disease [26]. Another major
limitation of our present study is that ADT was not uniformly
administered, in terms of either presence or duration, to IR
and HR patients. Additionally, long-term ADT (>6 months)
was relatively uncommonly used at our institution during the
period of the study. Although we could not control for ADT
duration, given that this was not uniformly available for all
patients, we did adjust for ADT use in our multivariate models,
and found that our risk-stratification system remained robust.
We also note that the criteria we used to define VHR disease
were slightly different than that of the NCCN and Johns
Hopkins [4]. We chose to use ≥50% of PPBC instead of >4
cores with a total Gleason score ≥8 because PPBC does not
depend on the absolute number of cores sampled, unlike the
number of high-grade cores, which can be increased simply by
taking more biopsies. Moreover, PPBC is a better-established
adverse risk factor that has been validated across numerous
independent datasets [7,9,27], and PPBC is already used in the
definition of UIR, allowing for harmonisation of the UIR and
VHR stratifications.
In summary, we have proposed a modification to the NCCN
risk-stratification system that is modestly more accurate in
predicting outcome than the classic NCCN system. Further,
we think that it may more accurately group patients who
would benefit from similar treatment paradigms. These results
require validation in independent datasets. Further refinement
of risk stratification for prostate cancer using imaging,
genomics, proteomics, and novel molecular biomarkers will
hopefully continue to improve our ability to personalise
therapy for patients.
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